Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study
The real-world OS and PFS rates were lower than those of the IMBrave trial, most likely because 43% of our patients did not meet the inclusion criteria. We conclude that the combination of atezolizumab and bevacizumab is a safe and effective option for patients with unresectable hepatocellular carcinoma patients with manageable toxicities.
Authors
- Merin Babu (ORCID: https://orcid.org/0000-0002-3384-6497)
- Nikhil Krishna Haridas (ORCID: https://orcid.org/0000-0002-6906-1261)
- W.M. Jose (ORCID: https://orcid.org/0000-0002-5494-7158)
- Sumi Soman
- Abhinav Menon
- K Pavithran (ORCID: https://orcid.org/0000-0002-6129-5709)
- Arun Valsan (ORCID: https://orcid.org/0000-0002-8410-9665)
- Shine Sadasivan
- Rakesh MP
- Ashok Sebastian Komaranchath
- Arun Warrier
- Manjima P Nair
- Mohammed Thabrez
Institutions
- Amrita Institute of Medical Sciences and Research Centre (IN)
- Aster Medcity (IN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s12885-025-14400-9
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Amrita Vishwa Vidyapeetham University